CONMED’s (CNMD) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of CONMED (NYSE:CNMD) in a research note released on Thursday morning,Benzinga reports.

Several other research analysts also recently commented on the company. Zacks Research downgraded CONMED from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. Wells Fargo & Company lowered their price objective on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, January 21st. JPMorgan Chase & Co. reduced their price target on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Finally, Bank of America dropped their price objective on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $52.83.

CONMED Price Performance

Shares of NYSE CNMD opened at $38.30 on Thursday. The stock has a market cap of $1.19 billion, a P/E ratio of 25.36, a P/E/G ratio of 1.66 and a beta of 0.96. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. CONMED has a fifty-two week low of $35.37 and a fifty-two week high of $74.70. The firm’s 50-day simple moving average is $41.33 and its 200 day simple moving average is $46.33.

CONMED (NYSE:CNMD) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.11. The company had revenue of $373.20 million for the quarter, compared to the consensus estimate of $366.88 million. CONMED had a return on equity of 14.36% and a net margin of 3.42%.The firm’s revenue was up 7.9% compared to the same quarter last year. During the same period last year, the business posted $1.34 earnings per share. Equities analysts expect that CONMED will post 4.35 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. New York State Teachers Retirement System boosted its holdings in CONMED by 1.6% during the fourth quarter. New York State Teachers Retirement System now owns 45,592 shares of the company’s stock valued at $1,851,000 after purchasing an additional 728 shares in the last quarter. Comerica Bank raised its holdings in shares of CONMED by 83.1% in the 4th quarter. Comerica Bank now owns 56,271 shares of the company’s stock worth $2,285,000 after buying an additional 25,533 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of CONMED by 9.8% during the 4th quarter. Sanctuary Advisors LLC now owns 7,335 shares of the company’s stock worth $298,000 after buying an additional 652 shares during the period. Vanguard Group Inc. boosted its stake in CONMED by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 3,684,439 shares of the company’s stock valued at $149,588,000 after buying an additional 73,533 shares in the last quarter. Finally, HB Wealth Management LLC bought a new stake in CONMED in the fourth quarter valued at $649,000.

CONMED News Roundup

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 results beat analysts: CONMED reported $1.43 EPS (vs. $1.32 est.) and $373.2M revenue (vs. $366.9M est.), with revenue up ~7.9% year-over-year — this is the primary catalyst cited for the stock lift. Conmed: Q4 Earnings Snapshot
• Positive Sentiment: Gross-margin and surgical/orthopedic strength highlighted: coverage notes improved gross margin and outperformance in ortho/surgical segments drove the beat and underpin management’s 2026 outlook. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analyst note: Wells Fargo nudged its price target up to $42 (equal-weight), signaling modest upside from current levels and validating the quarter’s credibility. Benzinga
• Positive Sentiment: Management commentary and outlook: call highlights and deep-dive pieces emphasize strategic refocusing and ortho momentum setting the tone for 2026 expectations. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Earnings call transcripts and coverage are widely available for deeper read — useful for investors wanting management detail and segment-level commentary. Earnings Call Transcript
• Neutral Sentiment: Street posture mixed: Needham reaffirmed a Hold rating, indicating some analysts remain cautious despite the beat. Benzinga
• Neutral Sentiment: Analyst models: sell-side consensus still implies moderate 2026 earnings (consensus ~4.35 EPS), so follow-through depends on sustained ortho/surgical momentum and margin trends. Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Technical/valuation headwinds remain: the stock still trades well below its 52‑week high and under longer-term moving averages, so multiple expansion may be limited absent sustained execution.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.